

# Index

## A

*Actinobacillus equuli*, 149  
*Aeromonas hydrophila*, 130  
Aminoglycoside resistance, 234  
Aminoglycosides, 31  
Animalcules, 42  
Antibiotic resistance  
  absence of target, 35  
  drug modification, 37–38  
  drug target modification, 36–37  
  efflux pumps, 35–36  
  MRSA, 38  
  mycobacteria, 34–35  
  target bypassing, 37  
Antibiotics  
  aminoglycosides, 31  
  antibacterial antibiotics, 27  
  antifungal agents, 25–26  
  antimicrobial chemotherapy, 22–23  
  antimycobacterial agents, 34  
  antiprotozoal agents, 26–27  
  antiviral agents, 24–25  
   $\beta$ -lactams, 28–29  
  cell envelope, 27  
  chloramphenicol, 32  
  cidal and static drugs, 21  
  cycloserine and fosfomycin, 27–28  
  DNA, 29–30  
  fusidic acid, 32–33  
  glycopeptides, 28  
  macrolides and lincosamides, 32  
  membrane integrity, 29  
  minimum bactericidal concentration, 22  
  minimum inhibitory concentration, 21  
  mupirocin, 33  
  oxazolidones, 33  
  protein synthesis, 30–31

  RNA synthesis, 30  
  selective toxicity, 23–24  
  streptogramins, 33  
  synthetic compounds, 20  
  tetracyclines, 31–32  
Antifungal agents, 25–26  
Antimicrobial resistance  
  aminoglycoside resistance, 234  
  biofilm formation, 226  
  *Citrobacter freundii*, 227  
  development and use, 224  
  *Enterobacter cloacae*, 227  
  glycopeptide resistance, 236–237  
  *Klebsiella pneumoniae*, 229  
  macrolide and lincosamide resistance, 237  
  mechanisms, 225–228  
  meticillin-resistance in staphylococci,  
    230–232  
  *Pseudomonas aeruginosa*, 227  
  quinolone and fluoroquinolone resistance,  
    235–236  
  spectrum  $\beta$ -lactamases, 229–230  
  tetracycline resistance, 232  
  toxic effects, 225  
  trimethoprim resistance, 233  
Antimicrobial therapy, 180  
Antimycobacterial Agents, 34  
Antiprotozoal agents, 26–27  
Antiviral agents, 24–25

## B

Bacteria and archaea  
  algae, 6  
  cell membranes, 5  
  cell shape and arrangement, 4  
  cell size, 4

- Bacteria and archaea (*cont.*)
- cell walls, 5
  - external structure, 6
  - fungi, 6–7
  - genetic material, 5
  - microbes-animals interaction, 15–16
  - microbial growth, 11–12
  - microbial nutrition and “lifestyle,” 9–11
  - oxygen, 12–15
  - protozoa, 7–8
  - viruses, 8–9
- Bacterial adhesion, 50
- Bacteriology, 177
- Biofilmology, 48
- Biofilms, 191
- adhesion, 49–50
  - animals and humans, 43–45
  - antimicrobial agents, 57
  - antimicrobial tolerance, 57–58
  - biofilm model, 46–47
  - biofilm phenotype tolerant induction, 58
  - biofilm-related infections, 192–193
  - candidal biofilms, 62
  - clinical importance, 58–60
  - conditioning film development, 48–49
  - definition, 46
  - EPS, 50–52
  - historical perspective, 42–43
  - host defence mechanism, 56
  - infections management, 60–61
  - infectious disease process, 61
  - interfacial transfer process, 55
  - microcolony, 52–55
  - microorganisms, 45
  - phenotype tolerant induction, 58
  - sheltering effect, 56
  - substratum effects, 48–49
  - transport mechanism, 49
- $\beta$ -lactamase enzyme, 57
- $\beta$ -lactams, 28–29
- Bovine mastitis biofilm behavior
- definition, 206
  - Escherichia coli*, 211–215
  - Staphylococcus aureus*, 207–210
  - Streptococcus uberis*, 216–217
  - virulence factor, 206
- Bovine spongiform encephalopathy (BSE), 18
- Buruli ulcer (BU), 78
- C**
- Cardiovascular implants, 196
- infections, 197
- Catheter-related bloodstream infection, 195
- Cell-mediated immune (CMI), 115
- Central venous catheters, 195
- Chloramphenicol, 32
- Chronic obstructive pulmonary disease (COPD), 75
- Chronic wounds, horses
- antibiotic resistance, 163–164
  - bacterial biofilm, 157–158
  - bacteria role, 148–149
  - biofilm development, 150–152
  - biofilm residing bacteria removal, 165
  - biofilms and resistance, 162–163
  - biofilm visualizing methods, 159–160
  - clinical in vivo identification, biofilms, 152–153
  - colic surgery, 144
  - congo red agar, 160–161
  - coomassie brilliant blue stain, 155, 157
  - counter staining bacteria, 157–158
  - crystal violet assay, 161
  - elevated cortisone level, 147
  - gram stains, 154–157
  - healing, 144–145
  - iatrogenic factor, 147
  - in vitro evidence, biofilms, 160
  - in vitro visualisation, biofilms, 153–154
  - matrix metalloproteinases (MMPS), 148
  - microorganism removal, 166
  - necrotic tissue, 148
  - nutritional state, 147
  - pH, 147
  - poor/impaired blood and oxygen supply, 147
  - scanning electron microscopy, 158–159
  - tissue inhibitors of metalloproteinases, 148
  - trauma and surgical wound, 143–144
  - types, 145–146
  - wound location, 146
- Citrobacter freundii*, 227
- Clostridium botulinum*, 75
- Clostridium difficile*, 20
- Clostridium perfringens*, 85
- CMI. *See* Cell-mediated immune
- Congo red agar, 160–161
- Contact lenses, infection, 198
- COPD. *See* Chronic obstructive pulmonary disease
- Corynebacterium auriscanis*, 130
- Cycloserine, 27–28
- D**
- Dental caries, 138
- Dental plaque biofilms, 134–135

## Dogs and Cats

- fungal osteomyelitis, 188
- haematogenous osteomyelitis, 184–186
- iatrogenic causes, 187–188
- secondary to trauma, 186
- septic osteitis, 182, 183

**E**

- Endotracheal tube, biofilm, 195
- Enterobacter cloacae*, 227
- Enzyme-linked immunosorbent assays (ELISA), 114
- Episcopic differential interference contrast (EDIC), 91
- Escherichia coli*
  - adherence and invasion, 212–213
  - curli fibers support epithelial adherence, 211–212
  - immunity and competition, 213–214
  - intracellular persistence, 213
  - prevention and therapy, 214–215
  - replication, 213
- Eukaryotic microorganisms, 3–4
- Extracellular polymeric substance (EPS), 50–52, 70, 130

**F**

- Feeding tubes, 196
- Fish muscle proteins (FMPs), 92
- Fluorescent in situ hybridisation (FISH), 159
- Food-borne and water-borne biofilms
  - attachment and detachment processes, 87–88
  - effective sanitation strategies, 90
  - L. monocytogenes*, 88–89
  - pathogenic organisms, 88
- Fosfomycin, 27–28
- Frustrated phagocytosis, 162
- Fusidic acid, 32–33

**G**

- Glycocalyx, 43
- Glycopeptide resistance, 236–237
- Glycopeptides, 28
- Gravitational cell sedimentation, 49

**H**

- Helicobacter*, 80–81
- Horse

- haematogenous osteomyelitis, 177–178
- iatrogenic causes, 180, 181
- secondary to trauma, 179

**I**

- Infection and disease
  - antimicrobials, 116–118
  - antimicrobial treatments, 123
  - biofilm development, 113
  - cattle, 122–123
  - diagnosis, 113–114
  - dry period, 123–124
  - human and veterinary patients, 118
  - immune cells, 122
  - immune system responds, 114–116
  - lysozyme, 124
  - medical implant and prostheses, 120–121
  - phenotypic states, 112
  - somatic cells, 122
  - Staphylococcus aureus*, 121
  - Staphylococcus epidermidis*, 121
  - wounds, 118–119
- Intraoral lenses, 198

**K**

- Klebsiella pneumoniae*, 229

**L**

- Lincosamides, 32
- Listeria monocytogenes*, 80

**M**

- Macrolide and lincosamide resistance, 237
- Macrolides, 32
- Maggot therapy, 165
- Major histocompatibility complexes (MHC), 115
- M. avium paratuberculosis* (MAP), 79
- Medical devices
  - biofilm development, 192
  - biofilm formation, 199
  - prevention of medical device infection, 200
  - treatment of medical device-related infections, 200
- Metaphyseal infection, 184
- Methicillin-resistant *Staphylococcus aureus* (MRSA), 20
- Microcolony and biofilm formation
  - biofilm heterogeneity, 52

Microcolony and biofilm formation (*cont.*)

- homeostatic mechanism, 52
- microbial interaction, 53–55
- streaming, 53
- voids and pores, 53

## Microorganisms, 2–4

## Minimum inhibitory concentration (MIC), 225

## Mupirocin, 33

**N**

## Native valve endocarditis (NVE), 58

## Neonatal foal, 177–178

## Nitromidazole resistance, 238

## Non-cellular obligate parasites, 3

**O**

## Ophthalmic infections, 198

## Oral health animals

- animals and humans, 133
- antimicrobial therapies, 131
- biofilm microorganisms, 130
- cats/dogs, 132
- dental caries, 138
- dental plaque biofilms, 134–135
- opportunistic oral pathogens, 135
- periodontal diseases, 136–138
- planktonic growth, 133–134
- plaque control, 139
- plaque-mediated diseases, 135
- P. multocida*, 132
- prevention, 139
- systemic diseases, 138

## Orthopaedic devices, 197

## Osteomyelitis

- bacteriology, 177
- classifications, 176
- definition, 175
- dogs and cats (*See* Dogs and cats)
- horse (*See* Horse)
- pathophysiology, 176–177
- production animals, 188

## Oxazolidones, 33

**P**

## Pacemakers, 197

*Pasteurella canis*, 131*Pasteurella multocida*, 132

## Pathogen-associated molecular patterns (PAMPs), 115

## Pathophysiology, 176–177

## Periodontal diseases, 136–138

## Peritoneal catheters, 194

## Plaque-mediated diseases, 135

## Plasmid-mediated fluoroquinolone resistance, 235–236

## Polymerase chain reaction (PCR), 75

## Polymethylmethacrylate antibiotic, 182

## Polysaccharide intercellular adhesion (PIA), 47

## Postoperative infection (POI), 180, 181

## Prokaryotic microbes, 3

*Pseudomonas aeruginosa*, 227**Q**

## Quorum sensing molecules, 54, 151

**R**

## Radiology, 185

## Rifampicin resistance

- exopolysaccharide formation, 241
- nitromidazole resistance, 238
- persistent bacteria, 240
- reduced antimicrobial penetration, 239–240
- reduced growth, 240
- resistance arising in biofilms, 238–239
- resistance genes, 241

**S***Salmonella*, 82–83*Sarcocystis felis*, 119

## Septic osteitis, 182, 183

## Septic tenosynovitis, 179

*Shigella*, 83

## Somatic cell count (SCC), 122

Spectrum  $\beta$ -lactamases, 229–230

## Staphylococcal cassette chromosome (SCC), 74

*Staphylococcus aureus*, 121

## adherence, 207–209

## biofilm formation, 207–209

## invasion, 207–209

## therapy, 209–210

## vaccine development, 210

*Staphylococcus epidermidis*, 121*Staphylococcus hyicus*, 130*Streptococcus suis*, 86*Streptococcus uberis*, 216–217

## Streptogramins, 33

## Sutures, foreign materials, 198

**T**

- Tetracycline resistance, 232
- Tetracyclines, 31–32
- Toxic effects, 225
- Trimethoprim resistance, 233
- Tumour necrosis factor-  $\alpha$  (TNF-  $\alpha$ ), 115

**U**

- Urinary catheters, 200
  - biofilms, 193
- Urinary tract infection, 194

**V**

- Ventilator-associated pneumonia, 195

**Y**

- Yersinia* species, 84

**Z**

- Zidovudine (AZT), 25
- Zoonoses
  - emerging zoonoses, 19–20
  - farm animals, 18–19
  - pets, 19
  - routes of transmission, 17–18
- Zoonotic infections
  - Aeromonas hydrophila*, 77
  - Aspergillosis, 77–78
  - attachment and detachment processes, 87–88

- biofilm control strategies, 91–92
- biofilm formation and composition, 70–72
- B. pseudomallei*, 76
- Campylobacter* species, 81–82
- Candida spp.*, 78
- C. botulinum*, 85
- COPD, 75
- C. perfringens*, 85
- E. coli*, 84
- E. coli* 0157, 84
- effective sanitation strategies, 90
- fish tank granuloma, 78
- giardia* and *cryptosporidium*, 83–84
- harbour pathogens organisms, 70
- Helicobacter*, 80–81
- human infections, 73
- L. monocytogenes*, 80, 88–89
- L. pneumophila*, 75–76
- MAP, 79
- M. haemophilum* infections, 78–79
- microbial organisms, 72
- microorganisms, 77
- MRSA infections, 74
- pathogenic organisms, 88
- Salmonella* species, 82–83
- S. aureus*, 73
- S. epidermidis*, 73–74
- Shigella* species, 83
- S. intermedius*, 74–75
- S. suis*, 86
- staphylococcal infections, 72
- urinary infections, 74
- Vibrio* species, 87
- Yersinia* species, 84